From the *Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL; and †Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA.
Reg Anesth Pain Med. 2014 May-Jun;39(3):185-8. doi: 10.1097/AAP.0000000000000074.
In March of 2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act, ushering in an era of health care reform. Section 6002 of the bill, the Physician Payment Sunshine Act, requires manufacturers of drugs, devices, biological therapeutics, and medical supplies to disclose to the Centers for Medicare and Medicaid Services any payments or transfers of value to physicians. These reports are not meant to prohibit relationships between physicians and industry, but rather to generate a searchable public database illustrating the purpose of the payment, the entities involved, and the timing of each occurrence. Although the bill is meant to reveal physician-industry relationships, the question of how society at large and the medical field will interpret these data are unknown. The purpose of this article is to inform physicians of the components of the Physician Payment Sunshine Act. We discuss several resultant challenges and suggest a framework for preparing for transparency reporting and its potential effects.
2010 年 3 月，巴拉克·奥巴马总统签署了《患者保护与平价医疗法案》，这标志着医疗改革时代的到来。该法案的第 6002 条，即《医师支付阳光法案》，要求药品、器械、生物治疗药物和医疗用品的制造商向医疗保险和医疗补助服务中心披露向医生支付或转让的任何款项或价值。这些报告并不是要禁止医生和行业之间的关系，而是要生成一个可搜索的公共数据库，说明付款的目的、涉及的实体以及每次付款的时间。尽管该法案旨在揭示医生与行业的关系，但目前尚不清楚整个社会和医学界将如何解读这些数据。本文的目的是让医生了解《医师支付阳光法案》的组成部分。我们讨论了由此产生的一些挑战，并提出了一个为透明度报告做准备的框架及其潜在影响。
